Intensive Blood Pressure Control and Chronic Kidney Disease: Insights from the SPRINT Study

Overview of Blood Pressure Measurement

In a follow-up analysis of the SPRINT study, researchers investigated how intensive blood pressure control impacts the risk of chronic kidney disease. Blood pressure is measured through two levels: systolic blood pressure (SBP), which occurs during heart contraction, and diastolic blood pressure (DBP), which occurs during heart relaxation. Normal resting blood pressure is defined as an SBP of up to 120 mmHg and a DBP of up to 80 mmHg. Persistent elevation above these thresholds may damage organs and increase the risk of heart disease, stroke, and kidney disease.

The Role of Antihypertensive Medications

Antihypertensive medications are designed to lower blood pressure and mitigate the risk of organ damage. Research indicates that SBP is a more critical risk factor for cardiovascular diseases than DBP. However, the optimal target SBP for treatment remains uncertain, as levels may differ among various patient subgroups based on additional medical conditions. Furthermore, any advantages of intensive treatment must be weighed against the potential side effects associated with higher doses or numbers of antihypertensive drugs.

The SPRINT Study: Design and Findings

The SPRINT Study (Systolic Blood Pressure Intervention Trial) aimed to evaluate the effects of intensive SBP control, where antihypertensive medications were adjusted monthly to reach a target SBP of less than 120 mmHg, compared to standard SBP control, targeting between 135-139 mmHg. The trial was halted after approximately three years due to a significant reduction in heart attack, stroke, or cardiovascular disease-related death in the intensive treatment group. Nevertheless, concerns arose regarding the impact of intensive SBP control on kidney function, as renal filtration is closely linked to hydrostatic pressure.

Subgroup Analysis and Kidney Health Outcomes

In the SPRINT Study, the intensive SBP treatment group exhibited a 3.5-fold increased risk of developing signs of chronic kidney disease throughout the trial. To gain a deeper understanding of these effects, investigators analyzed a subgroup of patients, publishing their findings in the Annals of Internal Medicine. The main study included 9,361 participants across 102 clinical centers in the USA and Puerto Rico, while the subgroup analysis focused on 6,662 participants without prior kidney disease. Kidney health was assessed through glomerular filtration rate testing.

After three years, 3.7% of the intensive control group showed signs of chronic kidney disease, contrasted with just 1% in the standard therapy group. Notably, none of the participants who developed chronic kidney disease progressed to end-stage kidney failure, and approximately 25% of those in the intensive therapy group recovered their renal function. Additionally, the intensive treatment group reported a 4.9% incidence of cardiovascular events or death, compared to 7.1% in the standard treatment group.

Conclusion and Future Considerations

Researchers concluded that while intensive treatment did heighten the risk of chronic kidney disease, the benefits of reduced cardiovascular events and all-cause mortality outweighed this risk. However, the long-term implications of intensive SBP reduction on kidney function remain to be fully understood. It is crucial for healthcare providers to carefully balance the benefits of intensive SBP management against the potential side effects of increased antihypertensive medication in individual patients.

Related Topics of Interest

– Could blood pressure drugs have potential as a medication for Alzheimer’s disease?
– The Blood Pressure Myth
– Effective Ways to Lower High Blood Pressure
– Targeting Immune Cells to Treat High Blood Pressure
– Do Nitrate-Rich Vegetables Lower High Blood Pressure?
– Effects of Mediterranean Diet on Endothelial Function and Blood Pressure
– Does dietary nitrate help decrease high blood pressure?
– Can a home blood pressure monitor predict disease risk?
– Taking many pills for high blood pressure? One pill may be just as effective.

Reference

Beddhu S, Rocco MV, Toto R, et al. Effects of intensive systolic blood pressure control on kidney and cardiovascular outcomes in persons without kidney disease. Ann Int Med. 2017;167:375-383. doi:10.7326/M16-2966.